The MEB also suggested how to show that ephedrine for myasthenia gravis meets the conditions for an N-of-1 trial: “inclusion of a positive control with a clear symptomatic effect (e.g., N-of-1 one trial with placebo, ephedrine and acetylcholinesterase inhibitor treatment periods) in combination with selection of a more responsive patient population. This evidence concerns the gene ACHE and myasthenia gravis.